Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.33
NAS:FLXN's Cash-to-Debt is ranked lower than
56% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. NAS:FLXN: 2.33 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:FLXN' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.09  Med: 7.42 Max: No Debt
Current: 2.33
2.09
No Debt
Equity-to-Asset 0.56
NAS:FLXN's Equity-to-Asset is ranked lower than
99.99% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:FLXN: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:FLXN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56  Med: 0.58 Max: 0.59
Current: 0.56
0.56
0.59
Debt-to-Equity 0.72
NAS:FLXN's Debt-to-Equity is ranked lower than
82% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NAS:FLXN: 0.72 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:FLXN' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.08  Med: 0.16 Max: 0.92
Current: 0.72
-0.08
0.92
Debt-to-EBITDA -1.15
NAS:FLXN's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NAS:FLXN: -1.15 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:FLXN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.29  Med: -0.33 Max: -0.13
Current: -1.15
-1.29
-0.13
Piotroski F-Score: 4
Altman Z-Score: 1.97
WACC vs ROIC
8.96%
-1387.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -5682.78
NAS:FLXN's Operating Margin % is ranked lower than
99.99% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. NAS:FLXN: -5682.78 )
Ranked among companies with meaningful Operating Margin % only.
NAS:FLXN' s Operating Margin % Range Over the Past 10 Years
Min: -36529.86  Med: -36529.86 Max: -5682.78
Current: -5682.78
-36529.86
-5682.78
Net Margin % -6087.29
NAS:FLXN's Net Margin % is ranked lower than
99.99% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:FLXN: -6087.29 )
Ranked among companies with meaningful Net Margin % only.
NAS:FLXN' s Net Margin % Range Over the Past 10 Years
Min: -38727.04  Med: -38727.04 Max: -6087.29
Current: -6087.29
-38727.04
-6087.29
ROE % -75.62
NAS:FLXN's ROE % is ranked lower than
87% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. NAS:FLXN: -75.62 )
Ranked among companies with meaningful ROE % only.
NAS:FLXN' s ROE % Range Over the Past 10 Years
Min: -75.62  Med: -55.44 Max: -37.21
Current: -75.62
-75.62
-37.21
ROA % -43.88
NAS:FLXN's ROA % is ranked lower than
86% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. NAS:FLXN: -43.88 )
Ranked among companies with meaningful ROA % only.
NAS:FLXN' s ROA % Range Over the Past 10 Years
Min: -104.64  Med: -41.19 Max: -31.74
Current: -43.88
-104.64
-31.74
ROC (Joel Greenblatt) % -1226.16
NAS:FLXN's ROC (Joel Greenblatt) % is ranked lower than
91% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. NAS:FLXN: -1226.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:FLXN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -22032.35  Med: -3626.95 Max: -734.28
Current: -1226.16
-22032.35
-734.28
3-Year EBITDA Growth Rate -24.90
NAS:FLXN's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. NAS:FLXN: -24.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:FLXN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -28.25 Max: -1.3
Current: -24.9
3-Year EPS without NRI Growth Rate -28.30
NAS:FLXN's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. NAS:FLXN: -28.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:FLXN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.15 Max: -1.8
Current: -28.3
GuruFocus has detected 1 Warning Sign with Flexion Therapeutics Inc NAS:FLXN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:FLXN's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

FLXN Guru Trades in Q2 2017

Ron Baron 209,500 sh (+98.77%)
Chuck Royce 50,000 sh (unchged)
» More
Q3 2017

FLXN Guru Trades in Q3 2017

Ron Baron 209,500 sh (unchged)
Chuck Royce 50,000 sh (unchged)
» More
Q4 2017

FLXN Guru Trades in Q4 2017

Ron Baron 226,300 sh (+8.02%)
Chuck Royce 44,795 sh (-10.41%)
» More
Q1 2018

FLXN Guru Trades in Q1 2018

Chuck Royce 44,795 sh (unchged)
Ron Baron 176,300 sh (-22.09%)
» More
» Details

Insider Trades

Latest Guru Trades with FLXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2018-03-31 Reduce -22.09%0.01%$21.57 - $27.94 $ 27.7114%176,300
Ron Baron 2017-12-31 Add 8.02%$19.62 - $29.93 $ 27.7113%226,300
Ron Baron 2017-06-30 Add 98.77%0.01%$16.97 - $28.02 $ 27.7132%209,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Flexion Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:002880, TPE:1789, NAS:AMPH, SZSE:002900, ISX:KAEF, NAS:COLL, NAS:SCMP, TSX:GUD, XKRX:170900, BOM:540222, SZSE:002365, HKSE:00950, SHSE:600351, OSTO:BIOG B, SZSE:300723, NSE:STAR, SZSE:000650, SHSE:600829, NAS:EGRX, SZSE:300702 » details
Traded in other countries:F02.Germany,
Headquarter Location:USA
Flexion Therapeutics Inc is a development stage specialty pharmaceutical company. The Company is engaged in the development and commercialization of novel, long-acting, injectable pain therapies including anti-inflammatory and analgesic therapies.

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing clinical effect of intra articular corticosteroid treatment.

Top Ranked Articles about Flexion Therapeutics Inc

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — New Research Emphasizes Economic Growth
Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
Flexion Therapeutics Names David Arkowitz as Chief Financial Officer
Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018
Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress

Ratios

vs
industry
vs
history
PB Ratio 4.69
FLXN's PB Ratio is ranked lower than
69% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. FLXN: 4.69 )
Ranked among companies with meaningful PB Ratio only.
FLXN' s PB Ratio Range Over the Past 10 Years
Min: 3.12  Med: 3.85 Max: 4.83
Current: 4.69
3.12
4.83
PS Ratio 407.52
FLXN's PS Ratio is ranked lower than
99.99% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. FLXN: 407.52 )
Ranked among companies with meaningful PS Ratio only.
FLXN' s PS Ratio Range Over the Past 10 Years
Min: 329.56  Med: 402.73 Max: 2645
Current: 407.52
329.56
2645
EV-to-EBIT -5.92
FLXN's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. FLXN: -5.92 )
Ranked among companies with meaningful EV-to-EBIT only.
FLXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.13  Med: -5.4 Max: -4.4
Current: -5.92
-6.13
-4.4
EV-to-EBITDA -6.00
FLXN's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. FLXN: -6.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
FLXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: -5.5 Max: -4.5
Current: -6
-6.2
-4.5
EV-to-Revenue 325.99
FLXN's EV-to-Revenue is ranked lower than
99.99% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. FLXN: 325.99 )
Ranked among companies with meaningful EV-to-Revenue only.
FLXN' s EV-to-Revenue Range Over the Past 10 Years
Min: 247.5  Med: 320.95 Max: 2075.8
Current: 325.99
247.5
2075.8
Current Ratio 15.57
FLXN's Current Ratio is ranked higher than
95% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. FLXN: 15.57 )
Ranked among companies with meaningful Current Ratio only.
FLXN' s Current Ratio Range Over the Past 10 Years
Min: 3.3  Med: 13.02 Max: 32.27
Current: 15.57
3.3
32.27
Quick Ratio 15.46
FLXN's Quick Ratio is ranked higher than
95% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. FLXN: 15.46 )
Ranked among companies with meaningful Quick Ratio only.
FLXN' s Quick Ratio Range Over the Past 10 Years
Min: 3.3  Med: 13 Max: 32.27
Current: 15.46
3.3
32.27
Days Inventory 116.99
FLXN's Days Inventory is ranked lower than
99.99% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. FLXN: 116.99 )
Ranked among companies with meaningful Days Inventory only.
FLXN' s Days Inventory Range Over the Past 10 Years
Min: 116.99  Med: 82079.38 Max: 82079.38
Current: 116.99
116.99
82079.38
Days Sales Outstanding 343.23
FLXN's Days Sales Outstanding is ranked lower than
99.99% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. FLXN: 343.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 343.23  Med: 421.55 Max: 421.55
Current: 343.23
343.23
421.55
Days Payable 462.68
FLXN's Days Payable is ranked lower than
99.99% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. FLXN: 462.68 )
Ranked among companies with meaningful Days Payable only.
FLXN' s Days Payable Range Over the Past 10 Years
Min: 462.68  Med: 567757.5 Max: 567757.5
Current: 462.68
462.68
567757.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.60
FLXN's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. FLXN: -20.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FLXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.2  Med: -24.8 Max: 0
Current: -20.6
-43.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.29
FLXN's Price-to-Net-Cash is ranked higher than
77% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.33 vs. FLXN: 5.29 )
Ranked among companies with meaningful Price-to-Net-Cash only.
FLXN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.64  Med: 3.77 Max: 5.79
Current: 5.29
2.64
5.79
Price-to-Net-Current-Asset-Value 5.06
FLXN's Price-to-Net-Current-Asset-Value is ranked higher than
65% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.09 vs. FLXN: 5.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
FLXN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.6  Med: 3.72 Max: 5.62
Current: 5.06
2.6
5.62
Price-to-Tangible-Book 4.68
FLXN's Price-to-Tangible-Book is ranked lower than
61% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. FLXN: 4.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FLXN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.23  Med: 3.6 Max: 5.14
Current: 4.68
2.23
5.14
Price-to-Median-PS-Value 1.01
FLXN's Price-to-Median-PS-Value is ranked lower than
99.99% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. FLXN: 1.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FLXN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 3.48 Max: 6.14
Current: 1.01
0.81
6.14
Earnings Yield (Greenblatt) % -16.98
FLXN's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. FLXN: -16.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FLXN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.6  Med: -18.4 Max: -16.39
Current: -16.98
-22.6
-16.39

More Statistics

Revenue (TTM) (Mil) $2.55
EPS (TTM) $ -4.51
Beta0.96
Volatility39.65%
52-Week Range $17.61 - 32.25
Shares Outstanding (Mil)37.64

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}